<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108300</url>
  </required_header>
  <id_info>
    <org_study_id>CURE002</org_study_id>
    <nct_id>NCT03108300</nct_id>
  </id_info>
  <brief_title>Use of Propranolol Hydrochloride in the Treatment of Metastatic STS</brief_title>
  <official_title>The Use of Propranolol Hydrochloride Combined With Anthracyclin Based Chemotherapy in the Treatment of Metastatic Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fifty patients with pathological proof of malignant soft tissue sarcoma will receive
      Anthracyclin based chemotherapy combined with propranolol 40 mg twice daily.

        -  The primary end point : To assess Progression Free Survival (PFS)

        -  The secondary end points : To assess Overall Survival (OS) and Toxicity Profile
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Progression free survival (PFS) is defined as the time interval between the dates of first treatment administration and first observation of PD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>an average of 3 years</time_frame>
    <description>Overall Survival (OS) is defined as the time from the date of the first treatment administration to the date of death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Malignant Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>propranolol hydrochloride with Doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients suffering from metastatic soft tissue sarcoma will receive doxorubicin 60mg per square meter of body surface area every 21 days combined with propranolol hydrochloride 40mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol Hydrochloride</intervention_name>
    <description>propranolol hydrochloride is a beta-adrenergic receptor blocker</description>
    <arm_group_label>propranolol hydrochloride with Doxorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin is a chemotherapy which will be injected by a dose 60 mg per meter square of body surface area to be repeated every 21days</description>
    <arm_group_label>propranolol hydrochloride with Doxorubicin</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologic or cytologic diagnosis of malignant soft tissue sarcoma.

          2. ECOG less than or equal to 2 .

          3. Measurable disease according to the requirements of modified RECIST criteria.

          4. Age ≥ 19 years .

          5. Estimated life expectancy of at least 12 weeks .

          6. Adequate bone marrow reserve (white blood cells [WBC] ≥ 3.5 × 109 /L, neutrophils ≥
             1.5 × 109 /L, platelets ≥ 100 × 109 /L, and hemoglobin ≥ 9.0 gm/dL).

        Exclusion Criteria:

          1. Inadequate liver function (bilirubin &gt; 1.5 times upper normal limit [UNL] and alanine
             transaminase [ALT] or aspartate transaminase [AST] &gt; 3.0 UNL or up to 5.0 UNL in the
             presence of hepatic metastases).

          2. Inadequate renal function (creatinine &gt; 1.25 times UNL, creatinine clearance &lt;
             50mL/min).

          3. Serious concomitant systemic disorder incompatible with the study.

          4. Second primary malignancy (except in situ carcinoma of the cervix, adequately treated
             basal cell carcinoma of the skin, T1 vocal cord cancer in remission, or prior
             malignancy treated more than 5 years prior to enrollment without recurrence).

          5. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ahmed Nagy</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>propranolol hydrochloride</keyword>
  <keyword>sts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

